Explore innovative strategies in small cell lung cancer treatment, focusing on bone marrow protection to enhance patient outcomes and treatment durability.
Martin Dietrich, MD, PhD
Advertisement
Martin F. Dietrich, MD, PhD, is an assistant professor of internal medicine at the University of Central Florida College of Medicine and medical oncologist with Cancer Care Centers of Brevard and The US Oncology Network
Articles by Martin Dietrich, MD, PhD
Martin F. Dietrich, MD, PhD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.
Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.
Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.
Advertisement
Latest Updated Articles
The Relevance of MET Alterations to Targeted NSCLC TherapiesPublished: November 25th 2021 | Updated:
- Challenges for Following NCCN Guidelines for MET Inhibitors in NSCLC
Published: January 3rd 2022 | Updated:
CDK4/6 Inhibition Preserves Multiple Cell Lines in SCLCPublished: December 10th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5